Achaogen Inc buy melinda
Startpreis
25.08.18
/
50%
4,75 €
Kursziel
09.11.18
9,02 €
Rendite (%)
-49,91 %
Endpreis
09.11.18
2,38 €
Zusammenfassung
Diese Einschätzung wurde am 09.11.18 mit einem Endkurs von 2,38 € beendet. Herbe Verluste von -49,91 % verzeichnete die BUY Einschätzung von melinda. melinda hat 50% Zuversicht bei dieser EinschätzungRendite ohne Dividenden (%)
| Name | 1W | 1M | 1J | 3J |
|---|---|---|---|---|
| Achaogen Inc | - | - | - | - |
| iShares Core DAX® | 4,09 % | 3,54 % | 17,40 % | 20,33 % |
| iShares Nasdaq 100 | 1,42 % | 0,51 % | 39,21 % | 55,37 % |
| iShares Nikkei 225® | -1,57 % | -4,63 % | 15,73 % | 2,15 % |
| iShares S&P 500 | 1,82 % | 0,96 % | 30,40 % | 45,95 % |
Kommentare von melinda zu dieser Einschätzung
In der Diskussion Achaogen Inc diskutieren
SecteurRecherche biotechnologique et médicale Agenda 07/11 Publication de résultats
Discovers, develops and commercializes novel anti-bacterial to treat multi-drug resistant gram negative infections
Achaogen, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of antibacterial treatments for multi-drug resistant (MDR) gram-negative infections.
It offers Plazomicin to treat bacterial illness, such as complicated urinary tract infection, blood stream infections, and other infections due to MDR Enterobacteriaceae.
The company was founded by Nathaniel E. David in June 2002 and is headquartered in South San Francisco, CA.
Achaogen, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of antibacterial treatments for multi-drug resistant (MDR) gram-negative infections.
It offers Plazomicin to treat bacterial illness, such as complicated urinary tract infection, blood stream infections, and other infections due to MDR Enterobacteriaceae.
The company was founded by Nathaniel E. David in June 2002 and is headquartered in South San Francisco, CA.
Nombre d'employés : 230 personnes.
(Vom Mitglied beendet)